{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T01:18:22Z","timestamp":1725671902992},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T00:00:00Z","timestamp":1255478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Anaesthesist"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00101-009-1623-z","type":"journal-article","created":{"date-parts":[[2009,10,12]],"date-time":"2009-10-12T19:59:56Z","timestamp":1255377596000},"page":"1252-1255","source":"Crossref","is-referenced-by-count":6,"title":["Neue orale Antikoagulanzien"],"prefix":"10.1007","volume":"58","author":[{"given":"B.","family":"Heindl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Spannagl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,14]]},"reference":[{"key":"1623_CR1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1538-7836.2009.03429.x","volume":"7","author":"Crowther","year":"2009","unstructured":"Crowther MA, Warketin TE (2009) Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 7:107\u2013110","journal-title":"J Thromb Haemost"},{"key":"1623_CR2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.thromres.2008.07.007","volume":"123","author":"Desmurs-Clavel","year":"2009","unstructured":"Desmurs-Clavel H, Huchon C, Chatard B et al (2009) Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res 123:796\u2013798","journal-title":"Thromb Res"},{"key":"1623_CR3","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"Eriksson","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765\u20132775","journal-title":"N Engl J Med"},{"key":"1623_CR4","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178\u20132185","journal-title":"J Thromb Haemost"},{"key":"1623_CR5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949\u2013956","journal-title":"Lancet"},{"key":"1623_CR6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","volume":"157","author":"Ezekowitz","year":"2009","unstructured":"Ezekowitz MD, Connolly S, Parekh A et al (2009) Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157:805\u2013810","journal-title":"Am Heart J"},{"key":"1623_CR7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1538-7836.2009.03435.x","volume":"7","author":"Gatt","year":"2009","unstructured":"Gatt A, Riddell A, Van Veen JJ et al (2009) Optimizing warfarin reversal \u2013 an ex vivo study. J Thromb Haemost 7:1123\u20131127","journal-title":"J Thromb Haemost"},{"key":"1623_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0883-5403(09)00329-5","volume":"24","author":"Ginsberg","year":"2009","unstructured":"Ginsberg JS, Davidson BL, Comp PC et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1\u20139","journal-title":"J Arthroplasty"},{"key":"1623_CR9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"Kakkar","year":"2008","unstructured":"Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31\u201339","journal-title":"Lancet"},{"key":"1623_CR10","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776\u20132786","journal-title":"N Engl J Med"},{"key":"1623_CR11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.2006.02667.x","volume":"62","author":"Liesenfeld","year":"2006","unstructured":"Liesenfeld KH, Schafer HG, Troconiz IF et al (2006) Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 62:527\u2013537","journal-title":"Br J Clin Pharmacol"},{"key":"1623_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"Mega","year":"2009","unstructured":"Mega JL, Braunwald E, Mohanavelu S et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29\u201338","journal-title":"Lancet"},{"key":"1623_CR13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CPP45335","volume":"45","author":"Mueck","year":"2007","unstructured":"Mueck W, Becka M, Kubitza D et al (2007) Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban \u2013 an oral, direct factor Xa inhibitor \u2013 in healthy subjects. Int J Clin Pharmacol Ther 45:335\u2013344","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1623_CR14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","volume":"100","author":"Mueck","year":"2008","unstructured":"Mueck W, Borris LC, Dahl OE et al (2008) Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100:453\u2013461","journal-title":"Thromb Haemost"},{"key":"1623_CR15","first-page":"PP","volume":"7","author":"Olesen","year":"2009","unstructured":"Olesen JB, Christiansen K, Ingerslev J et al (2009) Haemostatic response to in vitro addition of recombinant factor VIIa, prothrombin concentrate, or concentrate of factor IX\/X in blood spiked with a direct Xa inhibitor. J Thromb Haemost 7(S2):PP-MO-386","journal-title":"J Thromb Haemost"},{"key":"1623_CR16","first-page":"PP","volume":"7","author":"Perzborn","year":"2009","unstructured":"Perzborn E, Trabandt A, Selbach K et al (2009) Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. J Thromb Haemost 7(S2):PP-MO-183","journal-title":"J Thromb Haemost"},{"key":"1623_CR17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","volume":"64","author":"Stangier","year":"2007","unstructured":"Stangier J, Rathgen K, Stahle H et al (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292\u2013303","journal-title":"Br J Clin Pharmacol"},{"key":"1623_CR18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.thromres.2007.09.002","volume":"122","author":"Tanaka","year":"2008","unstructured":"Tanaka KA, Szlam F, Dickneite G et al (2008) Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 122:117\u2013123","journal-title":"Thromb Res"}],"container-title":["Der Anaesthesist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-009-1623-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00101-009-1623-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-009-1623-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T02:57:09Z","timestamp":1558580229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00101-009-1623-z"}},"subtitle":["Konsequenzen f\u00fcr die perioperative Gerinnungsdiagnostik und -therapie"],"short-title":[],"issued":{"date-parts":[[2009,10,14]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1007\/s00101-009-1623-z","relation":{},"ISSN":["0003-2417","1432-055X"],"issn-type":[{"value":"0003-2417","type":"print"},{"value":"1432-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,14]]}}}